Jaktinib (JAK1/2 inhibitor): A momelotinib derivative with similar activity and optimized dosing schedule

This publication has 21 references indexed in Scilit:

• Momelotinib therapy for myelofibrosis: a 7-year follow-up
  Blood Cancer Journal, 2018
• SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
  Journal of Clinical Oncology, 2017
• Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
  Leukemia, 2017
• Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
  JAMA Oncology, 2015
• Momelotinib treatment‐emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
  British Journal of Haematology, 2014
• Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
  Leukemia, 2013
• Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
  Journal of Clinical Oncology, 2011
• Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
  New England Journal of Medicine, 2010
• CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
  Leukemia, 2009
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
  Nature, 2005